3 completed, 1 active not recruiting, 1 recruiting. 5 Phase 3, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 5 | Completed 3, Active not recruiting 1, Recruiting 1 |
| Phase 2 | 2 | Completed 1, Recruiting 1 |
Follow Tuberculosis, MDR: new trials by email Literature Review of Tuberculosis, MDR trials Research Report on Tuberculosis, MDR
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Program for Rifampicin-Resistant Disease With Stratified Medicine for Tuberculosis Bedaquiline, Linezolid, Pretomanid - Tuberculosis, Pulmonary, Tuberculosis, Multidrug-Resistant | Phase 2 / Phase 3 | Recruiting | University of California, San Francisco | 400 | 2025-10-03 | 2026-09-02 |
| Protecting Households On Exposure to Newly Diagnosed Index Multidrug-Resistant Tuberculosis Patients Delamanid (DLM), Isoniazid (INH), Pyridoxine (vitamin B6) - Tuberculosis, MDR | Phase 3 | Active not recruiting | National Institute of Allergy and Infectious Diseases (NIAID) | 5832 | 2019-06-03 | 2026-11-02 |
| Trial to Evaluate the Efficacy, Safety and Tolerability of BPaMZ in Drug-Sensitive (DS-TB) Adult Patients and Drug-Resistant (DR-TB) Adult Patients Pretomanid, Bedaquiline, Moxifloxacin - Tuberculosis, Pulmonary, Tuberculosis, Multidrug-Resistant | Phase 2 / Phase 3 | Completed | Global Alliance for TB Drug Development | 455 | 2018-07-30 | 2026-08-27 |
| Various Doses and Durations of Linezolid Plus Bedaquiline & Pretomanid in Participants With Drug Resistant Tuberculosis Pretomanid, Linezolid, Bedaquiline - Tuberculosis, Pulmonary, Tuberculosis, Multidrug-Resistant | Phase 3 | Completed | Global Alliance for TB Drug Development | 181 | 2017-11-21 | 2023-06-29 |
| FS-1 Drug for Treatment of Multiple Drug-resistant Tuberculosis FS-1, Placebo - Tuberculosis, MDR | Phase 3 | Completed | Scientific Center for Anti-infectious Drugs, Kazakhstan | 344 | 2013-12-01 | 2022-05-24 |
Tuberculosis (5) · Tuberculosis, Multidrug-Resistant (5) · Tuberculosis, Pulmonary (3) · Extensively Drug-Resistant Tuberculosis (1)
Actinomycetales Infections (5) · Bacterial Infections (5) · Bacterial Infections and Mycoses (5) · Gram-Positive Bacterial Infections (5) · Infections (5) · Mycobacterium Infections (5) · Lung Diseases (3) · Respiratory Tract Diseases (3) · Respiratory Tract Infections (3)
bedaquiline (3) · pretomanid (3) · Isoniazid (2) · Linezolid (2) · Moxifloxacin (2) · Ethambutol (1) · OPC-67683 (1) · Pyrazinamide (1) · Pyridoxine (1) · Rifampin (1) · Vitamin B 6 (1)
Global Alliance for TB Drug Development (2) · National Institute of Allergy and Infectious Diseases (NIAID) (1) · Scientific Center for Anti-infectious Drugs, Kazakhstan (1) · University of California, San Francisco (1)
South Africa (3) · Uganda (3) · Brazil (2) · Georgia (2) · Peru (2) · Philippines (2) · Russia (2) · Tanzania (2) · Vietnam (2) · Botswana (1) · Haiti (1) · India (1) · Kazakhstan (1) · Kenya (1) · Kyrgyzstan (1)
Amirkan A Azembayev, Cond.Phar.Sc. (1) · Amita Gupta, MD, MHS (1) · Anneke Hesseling, MD, PhD (1) · Francesca Conradie (1) · Gavin Churchyard, MBBCh MMed FRCP FCP(SA) PhD (1) · Morounfolu Olugbosi, MD MSc (1) · Susan Swindells, MBBS (1)